/DISCLAIMER · RESEARCH_COMPOUND

This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.

/PNC_27

Peptide

PNC-27

p53-Derived HDM2-Targeting Peptide (Investigational)

/HALF_LIFE

Not well characterized; expected short plasma stability typical of linear peptides (minutes to low hours) without specialized formulation

/DELIVERY

Preclinical studies have explored intratumoral, perilesional, or topical/locoregional administration; systemic delivery remains investigational.

/WHAT_IT_IS

PNC-27 is a synthetic peptide based on residues from the human p53 protein linked to a membrane-penetrating motif. In preclinical research it binds HDM2 localized on cancer-cell membranes and assembles into membrane pores, producing selective on-target cytotoxicity in vitro and in animal models.

/USAGE

Exploratory oncology research to study HDM2-targeted membrane disruption, tumor cell killing, and differential effects between malignant and non-malignant cells.

/MECHANISM_OF_ACTION

Binds HDM2 on cancer-cell membranes; peptide oligomerization forms transmembrane pores that rapidly disturb ionic gradients and induce necrotic/apoptotic cell death. Selectivity is hypothesized to stem from cancer-specific membrane HDM2 expression.

Reported Benefits

+Potent cytotoxicity against HDM2-positive cancer cells in vitro
+Activity reported across multiple tumor cell lines in preclinical studies
+Mechanistically distinct from DNA-damaging chemotherapeutics

Reported Side Effects

−Local irritation at administration site (preclinical)
−Potential off-target membrane toxicity/hemolysis at higher concentrations
−Unknown immunogenicity and systemic safety; not clinically approved

/STACKED_WITH

Use with standard-of-care comparators in study arms (e.g., doxorubicin) for benchmarkingHDM2 pathway modulators (research controls only)Formulation strategies (liposomes, hydrogels) to explore delivery and stability

/RESEARCH_NOTES

Highly investigational and not approved for therapeutic use. Published work is primarily in vitro/animal models; human evidence is limited and not definitive. Rigorous controls (HDM2 blockade/knockdown, non-target peptide analogs) are recommended to confirm on-target effects and rule out non-specific membrane lysis.

/REFERENCE

https://pubmed.ncbi.nlm.nih.gov/?term=PNC-27

/TRACK_THIS

Browse all 89 in the app.

MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.

Download iOS →Download Android →